Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02777385 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
A Phase 2 study, sponsored by Dan Zandberg.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02777385 is a Phase 2 study that has completed, run by Dan Zandberg. The registered enrollment target is 80 participants.
The verdict
NCT02777385, a Phase 2 study, has completed, sponsored by Dan Zandberg.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The goal of this research study is to learn which therapy order (adding pembrolizumab during vs. after cisplatin and radiation) may be more effective in treating head and neck cancer, as well as learn the side effects of these combinations. Pembrolizumab is an immune therapy, a drug that stimulates the immune system to fight cancer, and is FDA approved in lung cancer and melanoma.
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- RADIATION IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-05-31 |
| Est. Completion | 2023-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02777385
The ClinicalTrials.gov registry entry for NCT02777385 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dan Zandberg, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02777385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02777385 about?
NCT02777385 is a clinical study titled "Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer". The goal of this research study is to learn which therapy order (adding pembrolizumab during vs. after cisplatin and radiation) may be more effective in treating head and neck cancer, as well as learn the side effects of these combinations. Pembrolizumab is an immune therapy, a drug that stimulates ...
What is the current status of trial NCT02777385?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-05-31. Estimated completion is 2023-05-04.
What interventions are being tested in trial NCT02777385?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), IMRT (RADIATION).
Who is sponsoring clinical trial NCT02777385?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.